At Crinetics, we believe education and empathy are keys to inclusion and belonging. We recently hosted a dynamic, multi-perspective panel discussion in celebration of #PrideMonth where we focused on what being an #LGBTQ ally truly means. Thank you to all of our panelists for sharing your perspectives, and we look forward to putting these learnings into action.
Crinetics Pharmaceuticals
Biotechnology Research
San Diego, California 16,448 followers
Discovering drugs for endocrine diseases and endocrine-related tumors. #acromegaly #crinetics #CarcinoidSyndrome
About us
This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too. Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.
- Website
-
https://crinetics.com
External link for Crinetics Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2008
- Specialties
- Drug Discovery, Endocrinology, RareDisease, and Biotech
Locations
-
Primary
Get directions
6055 Lusk Blvd
San Diego, California 92121, US
Employees at Crinetics Pharmaceuticals
Updates
-
At Crinetics, we support people living with endocrine diseases. June is congenital adrenal hyperplasia (CAH) Month, and we encourage you to help us raise awareness of this difficult-to-manage condition. CAH affects the adrenal glands, resulting in hormonal imbalances that can be life-altering, or even life-threatening. There have been few medical advances for this disease over the last 70 years, but we’re committed to changing that with our unique drug discovery and development platform. For more information on our efforts, visit: https://bit.ly/3XghDQx
-
-
Our Chief Development Officer, Dana Pizzuti, MD, shares why #ENDO2024 is particularly exciting for Crinetics and highlights the encouraging strides we're making in our pipeline development.
-
At #ENDO2024 this past weekend, our Chief Commercial Officer, Jim Hassard, shared how Crinetics is addressing some of the most pressing challenges highlighted at this year's conference.
-
We’re pleased to announce initial findings at #ENDO2024 for our second clinical product candidate in two open-label studies for the treatment of Congenital Adrenal Hyperplasia and ACTH-dependent Cushing's syndrome. Learn more: https://bit.ly/3yFIwTw
-
At #ENDO2024, we shared the latest findings from our ongoing clinical studies in the treatment of endocrine-related diseases. Our data presented at this year’s meeting signify an important step forward in potentially bringing new and innovative treatment options to patients in need. In case you missed it, learn more about our data presented at ENDO here: https://bit.ly/4c64ihU
-
-
Lise Kjems, Crinetics' Senior Vice President, Endocrinology, talks about our recent investigational compounds and goals for product development while at #ENDO2024.
-
Michael Keeley, Vice President, Global Product Leadership, shares insights into Crinetics’ patient advocacy efforts at #ENDO2024 and beyond.
-
We will present new data at #ENDO2024 from two ongoing studies evaluating our second clinical product candidate in the treatment of congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Join us today at the Late-Breaking Poster Presentation session to explore the comprehensive data set from Cohort 1 of our CAH study. Learn more here: https://bit.ly/3wMyTlG